Ralliant (NYSE:RAL) Price Target Cut to $51.00 by Analysts at Citigroup

Ralliant (NYSE:RAL) had its price target dropped by stock analysts at Citigroup from $61.00 to $51.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 29.03% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a report on Monday, December 29th. Truist Financial dropped their price objective on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday. Barclays raised their price target on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Oppenheimer decreased their price objective on Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Morgan Stanley restated an “overweight” rating and set a $45.00 price target on shares of Ralliant in a research note on Friday. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $51.30.

Ralliant Stock Up 3.0%

Shares of NYSE:RAL traded up $1.14 during trading on Friday, hitting $39.53. 2,916,384 shares of the company were exchanged, compared to its average volume of 1,792,062. The firm’s 50 day moving average price is $51.72 and its 200-day moving average price is $46.77. Ralliant has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03. The stock has a market capitalization of $4.46 billion and a P/E ratio of 31.13.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. Ralliant’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Institutional Trading of Ralliant

Several institutional investors and hedge funds have recently modified their holdings of RAL. Nordea Investment Management AB purchased a new stake in shares of Ralliant in the second quarter valued at $29,477,000. Cullen Frost Bankers Inc. acquired a new stake in Ralliant during the 2nd quarter worth about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Ralliant in the second quarter worth approximately $1,410,000. JPMorgan Chase & Co. acquired a new stake in shares of Ralliant during the second quarter worth approximately $18,494,000. Finally, Allspring Global Investments Holdings LLC grew its position in Ralliant by 5,269.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock valued at $14,000,000 after purchasing an additional 311,134 shares in the last quarter.

Key Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target—a bullish analyst signal that can attract buying interest. RAL: Vertical Research upgrade
• Positive Sentiment: Ralliant earned a relative strength rating upgrade and hit a key technical benchmark, which can support short‑term momentum and algorithmic buying. Ralliant earns relative strength rating upgrade
• Neutral Sentiment: The company reported Q4 2025 results that slightly beat consensus on EPS ($0.69 vs. $0.67) and revenue ($554.6M vs. ~$543M), showing modest underlying revenue growth. These beats are offset by other items below. Ralliant Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Ralliant took a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment (primarily tied to the EA Elektro‑Automatik acquisition), producing a reported net loss of ~$1.4B and triggering a sharp selloff. This is the primary negative catalyst weighing on the stock. Ralliant Plunges on $1.4B Electric Vehicle Impairment Charge
• Negative Sentiment: Following the impairment and the big loss, multiple law firms have launched investigations into whether Ralliant and its officers complied with securities laws (Johnson Fistel, Holzer & Holzer, Block & Leviton), increasing legal uncertainty and potential headline risk. Johnson Fistel investigation notice Holzer & Holzer investor alert
• Negative Sentiment: Shares recently hit an all‑time low as investors reacted to the magnitude of the impairment and the company’s prior swing to large losses, underscoring elevated downside sensitivity to further negative news. Ralliant drops to all-time low

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.